Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Sirolimus, Tacrolimus and Thymoglobulin for GVHD Prophylaxis in Unrelated Donor Transplant
NCT00691015Phase 2Completed
- Sponsor
- Barbara Ann Karmanos Cancer Institute
- Start
- May 2008
- Primary completion
- Apr 2014
- Modality
- Recombinant Proteins and Enzymes, Antibody-Based Therapeutics
- Countries
- 1
01
Overview
Phase 2, open-label, single-arm trial of antithymocyte globulin rabbit in graft-versus-host disease (GVHD), sponsored by Barbara Ann Karmanos Cancer Institute. Primary endpoints: Incidence of Acute Graft-versus-host Disease (GVHD) at 100 days, Severity of Acute Graft-versus-host Disease (GVHD) at 100 days and 1 more. Started May 2008; status: completed.
02
Drugs
antithymocyte globulin rabbit
03
Conditions
graft-versus-host disease (GVHD)
Beyond the preview
Go deeper on NCT00691015.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT00691015.